About Obsidian Therapeutics
Obsidian Therapeutics is a publicly listed company based in Cambridge (United States) founded in 2015. Engineered cell and gene therapies are developed for multiple diseases. It operates on a HealthTech model. Obsidian Therapeutics has raised $325 million across 4 funding rounds from investors including Amgen, TD Securities and Citadel. The company has 80 employees. Its chief executive, as recorded, is Michael Gilman. Obsidian Therapeutics offers products and services including OBX-115 and cytoDRiVE® Platform. Its focus areas include Biotechnology and Cell and Gene Therapy. Its legal entity is Obsidian Therapeutics, Inc. Its competitors include BeiGene, Senti Biosciences and TScan Therapeutics; 3 of its 3 listed competitors have raised funding.
Company details
Obsidian Therapeutics is engaged in pioneering cell and gene therapy solutions. The company is recognized for leading the next generation of engineered therapeutics. Its proprietary cytoDRiVE platform is utilized to control protein function with FDA-approved small molecules. A novel pipeline of therapeutics is being developed, including the lead clinical program OBX-115 for advanced melanoma. Collaborations are established to enable discovery of innovative therapies. The focus is placed on precision medicines to address patient needs across various healthcare sectors.
- Headquarters Cambridge, United States
- Employees 80
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Phone•••• ••••
- Website obsidiantx.com
- Social LinkedIn X
- Legal Name Obsidian Therapeutics, Inc.
- Net Profit$149.05 M (USD)as on Dec 31, 2025
- EBITDA-$6.04 M (USD)57.25as on Dec 31, 2025
- Total Equity Funding$325M (USD)
in 4 rounds
- Latest Funding Round$350M (USD), Post-IPO
Aug 2026
- InvestorsAmgen
& 31 more
- Employee Count80
Products & Services of Obsidian Therapeutics
Obsidian Therapeutics offers a comprehensive portfolio of products and services, including OBX-115 and cytoDRiVE® Platform.
An investigational therapy for advanced melanoma treatment.
A platform for controlling therapeutic protein functions.
Funding Insights of Obsidian Therapeutics
Obsidian Therapeutics has successfully raised a total of $325M across 4 strategic funding rounds. The most recent funding activity was a Post-IPO round of $350 million completed in August 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $325M
- Total Rounds 4
- Last Round Post-IPO — $350M
- First Round $49.5M
(Dec 2017)
- Investors Count 32
All 4 funding rounds of Obsidian Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug 2026 | $350M | Post-IPO | – | – | |
| Apr 2024 | $160.5M | Series C | – | Wellington | |
| Sep 2021 | $115M | Series B | – | TCG Crossover | |
| Dec 2017 | $49.5M | Series A | – | Google Ventures |
32 investors in total: 32 institutional.
Investors in Obsidian Therapeutics
Obsidian Therapeutics has secured backing from 32 investors, including institutional and venture fund investors. Prominent investors backing the company include Amgen, TD Securities and Citadel.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Multi-stage investment firm invests in healthcare and life sciences companies | foresitecapital.com | New York, United States | ||
Multiple sectors are targeted for venture capital investments. | 1934 | janushenderson.com | London, United Kingdom | |
Private equity and venture capital fund focused on the healthcare sector | novoholdings.dk | Hellerup, Denmark | ||
Investment in transformative therapeutics is managed by the firm. | paradigmbiocapital.com | New York, United States | ||
Life Sciences focused VC firm investing in the US | 2010 | rtwfunds.com | New York, United States | |
Venture capital firm investing in life science and biotechnology sectors | 1980 | atlasventure.com | Cambridge, United States | |
Deep Track Capital is engaged in biotechnology investment activities. | deeptrackcapital.com | Greenwich, United States | ||
Private equity fund focused on the biotechnology sector | logoscapital.com | San Francisco, United States | ||
| tcgcrossover.com | ||||
Venture capital funding is provided by Samsara BioCapital in California. | samsaracap.com | Palo Alto, United States |
Investor details for Obsidian Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Obsidian Therapeutics
55 people are tracked at Obsidian Therapeutics (31 in leadership, 15 in board & advisors, 9 in team); the tracked headcount is 80.
| Name | Role | Group |
|---|---|---|
Michael Gilman | CEO | Leadership |
Parameswaran Hari | Chief Development Officer | Leadership |
Madan Jagasia | CEO | Leadership |
Rachel Burga | Associate Director | Leadership |
Kathryn Holderness | Director, CMC Operations And Strategy | Leadership |
Camille Renard Duteil | Director Clinical Science | Leadership |
Jeffrey Trigilio | Chief Financial And Operating Officer | Leadership |
Dana Alexander | Chief Technical Officer | Leadership |
Katie Aron | Senior Director | Leadership |
Dhruv Sethi | Senior Director | Leadership |
Ben Case | Director Of Fp&a | Leadership |
Jennifer Peterson | Chief People Officer | Leadership |
Emily Chuinard | Director, People Operations | Leadership |
Nic Betts | Vice President Of IT And Facilities | Leadership |
Zarine McDaniel | Associate Director Supply Chain, Cell & Gene Therapy | Leadership |
Kelly Higby | Associate Director, Facilities, Lab Operations, And EHS | Leadership |
Heather Boudreau | Senior Director, Controller | Leadership |
Gilles Lefebvre | Scientific Director | Leadership |
Amanda Kelly | Senior Director, Scientific And Strategic Communications | Leadership |
Prakash Prabhakar | Vice President, Clinical Operations & Translational Early Clinical Development | Leadership |
35 more people are available in the full profile.
Complete people profiles for Obsidian Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Obsidian Therapeutics
Obsidian Therapeutics is a publicly listed company on the NASDAQ with ticker symbol OBX in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- Listed onNASDAQ: OBX
- Listed entityObsidian Therapeutics, Inc.
- Exchange sectorHealth technology
- ISINUS67448A1060
- Share price$11.99 (-6.25% on the day) · 2026-10-13
- Market capitalisation$740.7M
- Price to earnings0.1
- EPS (diluted, trailing year)$161.87
- Volume (last session)377,259
Financials of Obsidian Therapeutics
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $149.1M | -$6.0M | |
| 2024 | -$19.0M | -$14.1M | |
| 2023 | -$59.1M | -$46.7M | |
| 2022 | -$62.2M | -$51.1M | |
| 2021 | -$80.5M | -$72.6M |
Detailed financial statements for Obsidian Therapeutics
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Obsidian Therapeutics
3 dated milestones of Obsidian Therapeutics across 11 years, from founding to its latest funding, stage changes and deals.
- Founded Obsidian Therapeutics is founded.
- Funding First funding round of $49.5M.
- Funding Latest funding round, Post-IPO, of $350.0M.
Competitors of Obsidian Therapeutics
Obsidian Therapeutics has 3 listed competitors in our database, 3 of them funded. They include BeiGene, Senti Biosciences and TScan Therapeutics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| beigene.com | 2010 | Cambridge, United States | $172M | 1,090 | Targeted and immune-oncology drugs for cancer treatment are developed. | |
| sentibio.com | 2016 | San Francisco, United States | $158M | Cell-based therapies for cancer treatment are developed. | ||
| tscan.com | 1995 | Boston, United States | $158.3M | 154 | T cell-based treatments for immunological and oncological disorders are developed. |
Detailed competitors of Obsidian Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Obsidian Therapeutics
The website of Obsidian Therapeutics (obsidiantx.com) receives about 8K visits a month and ranks #3,203,206 among all websites worldwide, #4,210 in Biotechnology and Pharmaceuticals.
- Monthly visits8K
▲ 27.2% vs previous month
- Unique visitors3K
per month
- Global rank#3,203,206
among all websites
- Category rank#4,210
Health · Biotechnology and Pharmaceuticals
- Bounce rate56%
- Pages per visit1.6
- Average visit23 sec
- DevicesDesktop 33% · Mobile 67%
Websites whose visitors overlap most with Obsidian Therapeutics. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| lyell.com | 100% | 14.3K | #3,232,661 | View details |
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as Obsidian Therapeutics (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Obsidian Therapeutics
Complete news archive for Obsidian Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Obsidian Therapeutics
Obsidian Therapeutics was founded in 2015 and raised its 1st funding round 2 years after it was founded.
Obsidian Therapeutics is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Michael Gilman is the CEO of Obsidian Therapeutics, as recorded in our data.
Obsidian Therapeutics is a funded company, having raised a total of $325M across 4 funding rounds to date. The company's 1st funding round was a Series A of $49.5M, raised on Dec 2017.
Obsidian Therapeutics has 80 employees.
Obsidian Therapeutics is engaged in pioneering cell and gene therapy solutions. The company is recognized for leading the next generation of engineered therapeutics. Its proprietary cytoDRiVE platform is utilized to control protein function with FDA-approved small molecules. A novel pipeline of therapeutics is being developed, including the lead clinical program OBX-115 for advanced melanoma. Collaborations are established to enable discovery of innovative therapies. The focus is placed on precision medicines to address patient needs across various healthcare sectors.
Obsidian Therapeutics's top competitors include BeiGene, Senti Biosciences and TScan Therapeutics.
Obsidian Therapeutics offers OBX-115 and cytoDRiVE® Platform.
Yes, Obsidian Therapeutics is publicly traded on NASDAQ under the ticker symbol OBX.
Obsidian Therapeutics has 32 investors. Key investors include Amgen, TD Securities, Citadel, Janus Henderson Investors, and RTW Investments.
Obsidian Therapeutics operates through Obsidian Therapeutics, Inc..